- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04310007
Testando a adição da pílula de quimioterapia, Cabozantinib, à imunoterapia padrão Nivolumab em comparação com a quimioterapia padrão para câncer de pulmão de células não pequenas
Um estudo randomizado de fase II de cabozantinibe e cabozantinibe mais nivolumabe versus quimioterapia padrão em pacientes com NSCLC não escamoso tratado anteriormente
This phase II trial compares cabozantinib alone and the combination of cabozantinib and nivolumab to standard chemotherapy in the treatment of patients with non-squamous non-small cell lung cancer (NSCLC). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as docetaxel, gemcitabine hydrochloride, paclitaxel, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cabozantinib alone or in combination with nivolumab may be more effective than standard chemotherapy in treating patients with non-small cell lung cancer.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVE:
I. To determine whether cabozantinib alone, or the combination of nivolumab and cabozantinib, as compared to standard chemotherapy alone, extends progression-free survival (PFS) for this patient population with non squamous NSCLC.
SECONDARY OBJECTIVES:
I. To determine the overall survival for each arm of the trial. II. To evaluate the best overall radiographic response rate for each arm of the trial.
III. To evaluate and describe the toxicity profile of monotherapy with cabozantinib, and the combination of nivolumab and cabozantinib in this patient population with non-squamous NSCLC.
EXPLORATORY IMAGING OBJECTIVES:
I. To describe time point tumor response assessment, overall best response, progression-free survival and overall survival using the conventional Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and the exploratory revised CHOI criteria with all measurements performed by the central review.
II. To compare the progression-free survival using the RECIST1.1 imaging response assessment measurements by site study personnel to those performed by central review.
EXPLORATORY CORRELATIVE OBJECTIVE:
I. To perform correlative biomarker research on tissue and blood biospecimens collected within this trial.
OUTLINE:
STEP 1: Patients are randomized to 1 of 3 arms.
ARM A: Patients receive cabozantinib S-malate orally (PO) once daily (QD). Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
ARM B: Patients receive cabozantinib S-malate PO QD and nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
ARM C: Patients receive ramucirumab IV over 30-60 minutes and docetaxel IV over 1 hour on day 1, or docetaxel IV over 1 hour on days 1 and 8, or gemcitabine hydrochloride IV on days 1 and 8, or paclitaxel IV over 3 hours on day 1, or nab-paclitaxel IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity and at the discretion of the treating physician.
STEP 2: Patients in Arm C experiencing disease progression are assigned to Arm Z.
ARM Z: Patients receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit.
Patients in all arms undergo echocardiogram (ECHO) as clinically indicated, computed tomography (CT) throughout the trial, and collection of blood on study.
After the completion of study treatment, patients are followed up every 3 months for up to 3 years.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Veterans Administration Medical Center - Birmingham
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Estados Unidos, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Estados Unidos, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Estados Unidos, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Estados Unidos, 99504
- Anchorage Radiation Therapy Center
-
Fairbanks, Alaska, Estados Unidos, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Goodyear, Arizona, Estados Unidos, 85338
- CTCA at Western Regional Medical Center
-
Kingman, Arizona, Estados Unidos, 86401
- Kingman Regional Medical Center
-
Phoenix, Arizona, Estados Unidos, 85004
- Cancer Center at Saint Joseph's
-
Tucson, Arizona, Estados Unidos, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Estados Unidos, 85719
- University of Arizona Cancer Center-North Campus
-
-
Arkansas
-
Fort Smith, Arkansas, Estados Unidos, 72903
- Mercy Hospital Fort Smith
-
Hot Springs, Arkansas, Estados Unidos, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Arroyo Grande, California, Estados Unidos, 93420
- PCR Oncology
-
Arroyo Grande, California, Estados Unidos, 93420
- Mission Hope Medical Oncology - Arroyo Grande
-
Burbank, California, Estados Unidos, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Carmichael, California, Estados Unidos, 95608
- Mercy San Juan Medical Center
-
Carmichael, California, Estados Unidos, 95608
- Mercy Cancer Center - Carmichael
-
Elk Grove, California, Estados Unidos, 95758
- Mercy Cancer Center - Elk Grove
-
Fremont, California, Estados Unidos, 94538
- Washington Health
-
Marysville, California, Estados Unidos, 95901
- Fremont - Rideout Cancer Center
-
Orange, California, Estados Unidos, 92868
- Saint Joseph Hospital - Orange
-
Palo Alto, California, Estados Unidos, 94304
- Stanford Cancer Institute Palo Alto
-
Rocklin, California, Estados Unidos, 95765
- Mercy Cancer Center - Rocklin
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Estados Unidos, 95816
- Mercy Cancer Center - Sacramento
-
San Luis Obispo, California, Estados Unidos, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Maria, California, Estados Unidos, 93444
- Mission Hope Medical Oncology - Santa Maria
-
Woodland, California, Estados Unidos, 95695
- Woodland Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Estados Unidos, 80012
- The Medical Center of Aurora
-
Boulder, Colorado, Estados Unidos, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Estados Unidos, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Centennial, Colorado, Estados Unidos, 80112
- Rocky Mountain Cancer Centers - Centennial
-
Colorado Springs, Colorado, Estados Unidos, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Estados Unidos, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Colorado Springs, Colorado, Estados Unidos, 80923
- Saint Francis Cancer Center
-
Denver, Colorado, Estados Unidos, 80218
- Presbyterian - Saint Lukes Medical Center - Health One
-
Denver, Colorado, Estados Unidos, 80220
- Rose Medical Center
-
Denver, Colorado, Estados Unidos, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Estados Unidos, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Estados Unidos, 80218
- Colorado Blood Cancer Institute
-
Denver, Colorado, Estados Unidos, 80204
- Cancer Center of Colorado at Sloan's Lake
-
Denver, Colorado, Estados Unidos, 80209
- The Women's Imaging Center
-
Denver, Colorado, Estados Unidos, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Estados Unidos, 80220
- Western Surgical Care
-
Denver, Colorado, Estados Unidos, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, Estados Unidos, 80210
- AdventHealth Porter
-
Durango, Colorado, Estados Unidos, 81301
- Mercy Medical Center
-
Durango, Colorado, Estados Unidos, 81301
- CommonSpirit Cancer Center Mercy
-
Englewood, Colorado, Estados Unidos, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Estados Unidos, 80113
- Swedish Medical Center
-
Englewood, Colorado, Estados Unidos, 80113
- Rocky Mountain Cancer Centers - Swedish
-
Englewood, Colorado, Estados Unidos, 80113
- The Melanoma and Skin Cancer Institute
-
Fort Collins, Colorado, Estados Unidos, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Estados Unidos, 80528
- Cancer Care and Hematology-Fort Collins
-
Golden, Colorado, Estados Unidos, 80401
- National Jewish Health-Western Hematology Oncology
-
Grand Junction, Colorado, Estados Unidos, 81501
- Saint Mary's Hospital and Regional Medical Center
-
Greeley, Colorado, Estados Unidos, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Estados Unidos, 80631
- Banner North Colorado Medical Center
-
Highlands Ranch, Colorado, Estados Unidos, 80129
- UCHealth Highlands Ranch Hospital
-
Lafayette, Colorado, Estados Unidos, 80026
- Good Samaritan Hospital - Cancer Centers of Colorado
-
Lakewood, Colorado, Estados Unidos, 80228
- Rocky Mountain Cancer Centers-Lakewood
-
Lakewood, Colorado, Estados Unidos, 80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton, Colorado, Estados Unidos, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Littleton, Colorado, Estados Unidos, 80122
- AdventHealth Littleton
-
Lone Tree, Colorado, Estados Unidos, 80124
- Sky Ridge Medical Center
-
Lone Tree, Colorado, Estados Unidos, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Longmont, Colorado, Estados Unidos, 80501
- Longmont United Hospital
-
Longmont, Colorado, Estados Unidos, 80501
- Rocky Mountain Cancer Centers-Longmont
-
Loveland, Colorado, Estados Unidos, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Estados Unidos, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Parker, Colorado, Estados Unidos, 80138
- AdventHealth Parker
-
Pueblo, Colorado, Estados Unidos, 81004
- Saint Mary Corwin Medical Center
-
Thornton, Colorado, Estados Unidos, 80260
- Rocky Mountain Cancer Centers-Thornton
-
Thornton, Colorado, Estados Unidos, 80260
- National Jewish Health-Northern Hematology Oncology
-
-
Connecticut
-
West Haven, Connecticut, Estados Unidos, 06516
- Veterans Affairs Connecticut Healthcare System-West Haven Campus
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- Mount Sinai Comprehensive Cancer Center at Aventura
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Holy Cross Hospital
-
Miami Beach, Florida, Estados Unidos, 33140
- Mount Sinai Medical Center
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University Hospital/Winship Cancer Institute
-
Savannah, Georgia, Estados Unidos, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Estados Unidos, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Estados Unidos, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Kootenai Health - Coeur d'Alene
-
Emmett, Idaho, Estados Unidos, 83617
- Walter Knox Memorial Hospital
-
Fruitland, Idaho, Estados Unidos, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Estados Unidos, 83642
- Idaho Urologic Institute-Meridian
-
Meridian, Idaho, Estados Unidos, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Estados Unidos, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Estados Unidos, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Estados Unidos, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Alton, Illinois, Estados Unidos, 62002
- OSF Saint Anthony's Health Center
-
Aurora, Illinois, Estados Unidos, 60504
- Rush-Copley Medical Center
-
Barrington, Illinois, Estados Unidos, 60010
- Advocate Good Shepherd Hospital
-
Bloomington, Illinois, Estados Unidos, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Estados Unidos, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Estados Unidos, 62902
- Memorial Hospital of Carbondale
-
Carterville, Illinois, Estados Unidos, 62918
- SIH Cancer Institute
-
Carthage, Illinois, Estados Unidos, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Estados Unidos, 62801
- Centralia Oncology Clinic
-
Centralia, Illinois, Estados Unidos, 62801
- Saint Mary's Hospital
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois
-
Chicago, Illinois, Estados Unidos, 60657
- Advocate Illinois Masonic Medical Center
-
Crystal Lake, Illinois, Estados Unidos, 60014
- AMG Crystal Lake - Oncology
-
Danville, Illinois, Estados Unidos, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Estados Unidos, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Estados Unidos, 61021
- Illinois CancerCare-Dixon
-
Downers Grove, Illinois, Estados Unidos, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Estados Unidos, 62401
- Carle Physician Group-Effingham
-
Elgin, Illinois, Estados Unidos, 60123
- Advocate Sherman Hospital
-
Eureka, Illinois, Estados Unidos, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Estados Unidos, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Estados Unidos, 61401
- Illinois CancerCare-Galesburg
-
Hazel Crest, Illinois, Estados Unidos, 60429
- Advocate South Suburban Hospital
-
Hines, Illinois, Estados Unidos, 60141
- Edward Hines Jr VA Hospital
-
Kewanee, Illinois, Estados Unidos, 61443
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Estados Unidos, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Estados Unidos, 60048
- AMG Libertyville - Oncology
-
Macomb, Illinois, Estados Unidos, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Estados Unidos, 61938
- Carle Physician Group-Mattoon/Charleston
-
Mount Vernon, Illinois, Estados Unidos, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Estados Unidos, 62269
- Cancer Care Center of O'Fallon
-
Oak Lawn, Illinois, Estados Unidos, 60453-2699
- Advocate Christ Medical Center
-
Ottawa, Illinois, Estados Unidos, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Estados Unidos, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Estados Unidos, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Estados Unidos, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Estados Unidos, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Estados Unidos, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Estados Unidos, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Estados Unidos, 61356
- Illinois CancerCare-Princeton
-
Rockford, Illinois, Estados Unidos, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield Clinic
-
Springfield, Illinois, Estados Unidos, 62781
- Springfield Memorial Hospital
-
Swansea, Illinois, Estados Unidos, 62226
- Southwest Illinois Health Services LLP
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
Urbana, Illinois, Estados Unidos, 61801
- The Carle Foundation Hospital
-
Washington, Illinois, Estados Unidos, 61571
- Illinois CancerCare - Washington
-
Yorkville, Illinois, Estados Unidos, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Richmond, Indiana, Estados Unidos, 47374
- Reid Health
-
South Bend, Indiana, Estados Unidos, 46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Estados Unidos, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Boone, Iowa, Estados Unidos, 50036
- McFarland Clinic - Boone
-
Carroll, Iowa, Estados Unidos, 51401
- Saint Anthony Regional Hospital
-
Clive, Iowa, Estados Unidos, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Estados Unidos, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Estados Unidos, 51503
- Alegent Health Mercy Hospital
-
Council Bluffs, Iowa, Estados Unidos, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Estados Unidos, 51503
- Methodist Jennie Edmundson Hospital
-
Creston, Iowa, Estados Unidos, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Estados Unidos, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Estados Unidos, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Estados Unidos, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Estados Unidos, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Estados Unidos, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Estados Unidos, 50501
- McFarland Clinic - Trinity Cancer Center
-
Fort Dodge, Iowa, Estados Unidos, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, Estados Unidos, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Estados Unidos, 50158
- McFarland Clinic - Marshalltown
-
West Des Moines, Iowa, Estados Unidos, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Estados Unidos, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Garden City, Kansas, Estados Unidos, 67846
- Central Care Cancer Center - Garden City
-
Great Bend, Kansas, Estados Unidos, 67530
- Central Care Cancer Center - Great Bend
-
Hays, Kansas, Estados Unidos, 67601
- HaysMed
-
Lawrence, Kansas, Estados Unidos, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Estados Unidos, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, Estados Unidos, 66213
- Saint Luke's South Hospital
-
Pittsburg, Kansas, Estados Unidos, 66762
- Freeman Physician Group of Pittsburg
-
Pittsburg, Kansas, Estados Unidos, 66762
- Mercy Hospital Pittsburg
-
Salina, Kansas, Estados Unidos, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Estados Unidos, 66606
- University of Kansas Health System Saint Francis Campus
-
-
Kentucky
-
Bardstown, Kentucky, Estados Unidos, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin, Kentucky, Estados Unidos, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Estados Unidos, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Estados Unidos, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Lexington, Kentucky, Estados Unidos, 40504
- CommonSpirit Saint Joseph Hospital - Lexington
-
London, Kentucky, Estados Unidos, 40741
- CommonSpirit Saint Joseph Hospital London
-
Louisville, Kentucky, Estados Unidos, 40202
- Jewish Hospital
-
Louisville, Kentucky, Estados Unidos, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Estados Unidos, 40215
- Saints Mary and Elizabeth Hospital
-
Mount Sterling, Kentucky, Estados Unidos, 40353
- CommonSpirit Saint Joseph Hospital Mount Sterling
-
Owensboro, Kentucky, Estados Unidos, 42303
- Owensboro Health Mitchell Memorial Cancer Center
-
Paducah, Kentucky, Estados Unidos, 42003
- Mercy Health - Paducah Cancer Center
-
Shepherdsville, Kentucky, Estados Unidos, 40165
- Jewish Hospital Medical Center South
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70805
- LSU Health Baton Rouge-North Clinic
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Estados Unidos, 70808
- Our Lady of The Lake
-
Baton Rouge, Louisiana, Estados Unidos, 70808
- Our Lady of the Lake Physician Group
-
Covington, Louisiana, Estados Unidos, 70433
- Northshore Oncology Associates-Covington
-
Houma, Louisiana, Estados Unidos, 70360
- Terrebonne General Medical Center
-
-
Maine
-
Augusta, Maine, Estados Unidos, 04330
- Harold Alfond Center for Cancer Care
-
Biddeford, Maine, Estados Unidos, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Sanford, Maine, Estados Unidos, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
South Portland, Maine, Estados Unidos, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21229
- Saint Agnes Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02118
- Boston Medical Center
-
Worcester, Massachusetts, Estados Unidos, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Adrian, Michigan, Estados Unidos, 49221
- Hickman Cancer Center
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek, Michigan, Estados Unidos, 49017
- Bronson Battle Creek
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health Medical Center - Canton
-
Caro, Michigan, Estados Unidos, 48723
- Caro Cancer Center
-
Chelsea, Michigan, Estados Unidos, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Estados Unidos, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Estados Unidos, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Estados Unidos, 48346
- Newland Medical Associates-Clarkston
-
Detroit, Michigan, Estados Unidos, 48236
- Henry Ford Health Saint John Hospital
-
East China Township, Michigan, Estados Unidos, 48054
- Henry Ford River District Hospital
-
Flint, Michigan, Estados Unidos, 48503
- Hurley Medical Center
-
Flint, Michigan, Estados Unidos, 48503
- Genesee Hematology Oncology PC
-
Flint, Michigan, Estados Unidos, 48503
- Genesys Hurley Cancer Institute
-
Flint, Michigan, Estados Unidos, 48503
- Cancer Hematology Centers - Flint
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grosse Pointe Woods, Michigan, Estados Unidos, 48236
- Henry Ford Saint John Hospital - Academic
-
Grosse Pointe Woods, Michigan, Estados Unidos, 48236
- Henry Ford Saint John Hospital - Breast
-
Grosse Pointe Woods, Michigan, Estados Unidos, 48236
- Henry Ford Saint John Hospital - Van Elslander
-
Kalamazoo, Michigan, Estados Unidos, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Estados Unidos, 49009
- Beacon Kalamazoo Cancer Center
-
Kalamazoo, Michigan, Estados Unidos, 49048
- Beacon Kalamazoo
-
Lansing, Michigan, Estados Unidos, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Estados Unidos, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Estados Unidos, 48154
- Hope Cancer Clinic
-
Macomb, Michigan, Estados Unidos, 48044
- Henry Ford Warren Hospital - Breast Macomb
-
Macomb, Michigan, Estados Unidos, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Marlette, Michigan, Estados Unidos, 48453
- Saint Mary's Oncology/Hematology Associates of Marlette
-
Monroe, Michigan, Estados Unidos, 48162
- Toledo Clinic Cancer Centers-Monroe
-
Muskegon, Michigan, Estados Unidos, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Estados Unidos, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Estados Unidos, 49444
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Novi, Michigan, Estados Unidos, 48374
- Henry Ford Health Providence Novi Hospital
-
Pontiac, Michigan, Estados Unidos, 48341
- Hope Cancer Center
-
Pontiac, Michigan, Estados Unidos, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Estados Unidos, 48341
- Michigan Healthcare Professionals Pontiac
-
Pontiac, Michigan, Estados Unidos, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Reed City, Michigan, Estados Unidos, 49677
- Corewell Health Reed City Hospital
-
Rochester Hills, Michigan, Estados Unidos, 48309
- Henry Ford Rochester Hospital
-
Saginaw, Michigan, Estados Unidos, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Estados Unidos, 48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Southfield, Michigan, Estados Unidos, 48075
- Henry Ford Health Providence Southfield Hospital
-
Sterling Heights, Michigan, Estados Unidos, 48312
- Bhadresh Nayak MD PC-Sterling Heights
-
Tawas City, Michigan, Estados Unidos, 48764
- MyMichigan Medical Center Tawas
-
Traverse City, Michigan, Estados Unidos, 49684
- Munson Medical Center
-
Warren, Michigan, Estados Unidos, 48088
- Advanced Breast Care Center PLLC
-
Warren, Michigan, Estados Unidos, 48093
- Macomb Hematology Oncology PC
-
Warren, Michigan, Estados Unidos, 48093
- Henry Ford Madison Heights Hospital - Breast
-
Warren, Michigan, Estados Unidos, 48093
- Henry Ford Health Warren Hospital
-
Warren, Michigan, Estados Unidos, 48093
- Henry Ford Warren Hospital - GLCMS
-
West Branch, Michigan, Estados Unidos, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Wyoming, Michigan, Estados Unidos, 49519
- University of Michigan Health - West
-
Ypsilanti, Michigan, Estados Unidos, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Ypsilanti, Michigan, Estados Unidos, 48106
- Huron Gastroenterology PC
-
-
Minnesota
-
Aitkin, Minnesota, Estados Unidos, 56431
- Riverwood Healthcare Center
-
Baxter, Minnesota, Estados Unidos, 56425
- Essentia Health - Baxter Clinic
-
Brainerd, Minnesota, Estados Unidos, 56401
- Essentia Health Saint Joseph's Medical Center
-
Burnsville, Minnesota, Estados Unidos, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, Estados Unidos, 55337
- Minnesota Oncology - Burnsville
-
Cambridge, Minnesota, Estados Unidos, 55008
- Cambridge Medical Center
-
Coon Rapids, Minnesota, Estados Unidos, 55433
- Mercy Hospital
-
Deer River, Minnesota, Estados Unidos, 56636
- Essentia Health - Deer River Clinic
-
Detroit Lakes, Minnesota, Estados Unidos, 56501
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Estados Unidos, 55805
- Essentia Health Cancer Center
-
Duluth, Minnesota, Estados Unidos, 55805
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Estados Unidos, 55805
- Miller-Dwan Hospital
-
Edina, Minnesota, Estados Unidos, 55435
- Fairview Southdale Hospital
-
Ely, Minnesota, Estados Unidos, 55731
- Essentia Health - Ely Clinic
-
Fergus Falls, Minnesota, Estados Unidos, 56537
- Lake Region Healthcare Corporation-Cancer Care
-
Fosston, Minnesota, Estados Unidos, 56542
- Essentia Health - Fosston
-
Fridley, Minnesota, Estados Unidos, 55432
- Unity Hospital
-
Hibbing, Minnesota, Estados Unidos, 55746
- Essentia Health Hibbing Clinic
-
International Falls, Minnesota, Estados Unidos, 56649
- Essentia Health - International Falls Clinic
-
Maple Grove, Minnesota, Estados Unidos, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Estados Unidos, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Estados Unidos, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Estados Unidos, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Estados Unidos, 55454
- Health Partners Inc
-
Monticello, Minnesota, Estados Unidos, 55362
- Monticello Cancer Center
-
Moose Lake, Minnesota, Estados Unidos, 55767
- Essentia Health - Moose Lake Clinic
-
New Ulm, Minnesota, Estados Unidos, 56073
- New Ulm Medical Center
-
Park Rapids, Minnesota, Estados Unidos, 56470
- Essentia Health - Park Rapids
-
Princeton, Minnesota, Estados Unidos, 55371
- Fairview Northland Medical Center
-
Robbinsdale, Minnesota, Estados Unidos, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Estados Unidos, 55102
- United Hospital
-
Sandstone, Minnesota, Estados Unidos, 55072
- Essentia Health Sandstone
-
Shakopee, Minnesota, Estados Unidos, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Estados Unidos, 55082
- Lakeview Hospital
-
Virginia, Minnesota, Estados Unidos, 55792
- Essentia Health Virginia Clinic
-
Waconia, Minnesota, Estados Unidos, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Estados Unidos, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Estados Unidos, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, Estados Unidos, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Ballwin, Missouri, Estados Unidos, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Bolivar, Missouri, Estados Unidos, 65613
- Central Care Cancer Center - Bolivar
-
Branson, Missouri, Estados Unidos, 65616
- Cox Cancer Center Branson
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Mercy Cancer Center - Cape Girardeau
-
City of Saint Peters, Missouri, Estados Unidos, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Columbia, Missouri, Estados Unidos, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Creve Coeur, Missouri, Estados Unidos, 63141
- Siteman Cancer Center at West County Hospital
-
Farmington, Missouri, Estados Unidos, 63640
- Parkland Health Center - Farmington
-
Jefferson City, Missouri, Estados Unidos, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Estados Unidos, 64804
- Freeman Health System
-
Joplin, Missouri, Estados Unidos, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Estados Unidos, 64111
- Saint Luke's Hospital of Kansas City
-
Kansas City, Missouri, Estados Unidos, 64108
- University Health Truman Medical Center
-
Lee's Summit, Missouri, Estados Unidos, 64086
- Saint Luke's East - Lee's Summit
-
Rolla, Missouri, Estados Unidos, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Estados Unidos, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Estados Unidos, 64506
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Estados Unidos, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Estados Unidos, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Estados Unidos, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Estados Unidos, 63136
- Siteman Cancer Center at Christian Hospital
-
St Louis, Missouri, Estados Unidos, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Estados Unidos, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Estados Unidos, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Estados Unidos, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Estados Unidos, 63080
- Missouri Baptist Sullivan Hospital
-
Washington, Missouri, Estados Unidos, 63090
- Mercy Hospital Washington
-
-
Montana
-
Anaconda, Montana, Estados Unidos, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Estados Unidos, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Estados Unidos, 59101
- Saint Vincent Healthcare
-
Billings, Montana, Estados Unidos, 59102
- Saint Vincent Frontier Cancer Center
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Estados Unidos, 59405
- Great Falls Clinic
-
Great Falls, Montana, Estados Unidos, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Estados Unidos, 59901
- Logan Health Medical Center
-
Missoula, Montana, Estados Unidos, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Estados Unidos, 59804
- Community Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Estados Unidos, 68123
- Nebraska Medicine-Bellevue
-
Grand Island, Nebraska, Estados Unidos, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Estados Unidos, 68847
- CHI Health Good Samaritan
-
Lincoln, Nebraska, Estados Unidos, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Estados Unidos, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Estados Unidos, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Estados Unidos, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Estados Unidos, 68118
- Nebraska Medicine-Village Pointe
-
Omaha, Nebraska, Estados Unidos, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Estados Unidos, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Estados Unidos, 68114
- Oncology Associates PC
-
Omaha, Nebraska, Estados Unidos, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
Papillion, Nebraska, Estados Unidos, 68046
- Midlands Community Hospital
-
-
Nevada
-
Carson City, Nevada, Estados Unidos, 89703
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Estados Unidos, 89052
- Comprehensive Cancer Centers of Nevada - Henderson
-
Henderson, Nevada, Estados Unidos, 89052
- Cancer and Blood Specialists-Henderson
-
Henderson, Nevada, Estados Unidos, 89052
- Las Vegas Cancer Center-Henderson
-
Henderson, Nevada, Estados Unidos, 89074
- Comprehensive Cancer Centers of Nevada-Southeast Henderson
-
Henderson, Nevada, Estados Unidos, 89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Henderson, Nevada, Estados Unidos, 89074
- Las Vegas Urology - Green Valley
-
Henderson, Nevada, Estados Unidos, 89074
- Las Vegas Urology - Pebble
-
Henderson, Nevada, Estados Unidos, 89074
- Urology Specialists of Nevada - Green Valley
-
Henderson, Nevada, Estados Unidos, 89074
- Oncology Las Vegas - Henderson
-
Las Vegas, Nevada, Estados Unidos, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Estados Unidos, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Estados Unidos, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Estados Unidos, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, Estados Unidos, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas, Nevada, Estados Unidos, 89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Estados Unidos, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Estados Unidos, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Estados Unidos, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Estados Unidos, 89144
- Comprehensive Cancer Centers of Nevada-Summerlin
-
Las Vegas, Nevada, Estados Unidos, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Estados Unidos, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Estados Unidos, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
- Cancer and Blood Specialists-Shadow
-
Las Vegas, Nevada, Estados Unidos, 89109
- HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
-
Las Vegas, Nevada, Estados Unidos, 89113
- HealthCare Partners Medical Group Oncology/Hematology-San Martin
-
Las Vegas, Nevada, Estados Unidos, 89128
- Cancer and Blood Specialists-Tenaya
-
Las Vegas, Nevada, Estados Unidos, 89128
- HealthCare Partners Medical Group Oncology/Hematology-Tenaya
-
Las Vegas, Nevada, Estados Unidos, 89148-2405
- Las Vegas Cancer Center-Medical Center
-
Las Vegas, Nevada, Estados Unidos, 89149
- HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
-
Las Vegas, Nevada, Estados Unidos, 89128
- Ann M Wierman MD LTD
-
Las Vegas, Nevada, Estados Unidos, 89074
- Las Vegas Urology - Pecos
-
Las Vegas, Nevada, Estados Unidos, 89102
- Desert West Surgery
-
Las Vegas, Nevada, Estados Unidos, 89103
- Hope Cancer Care of Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
- Urology Specialists of Nevada - Central
-
Las Vegas, Nevada, Estados Unidos, 89113
- Las Vegas Prostate Cancer Center
-
Las Vegas, Nevada, Estados Unidos, 89113
- Las Vegas Urology - Sunset
-
Las Vegas, Nevada, Estados Unidos, 89128
- Las Vegas Urology - Cathedral Rock
-
Las Vegas, Nevada, Estados Unidos, 89128
- Las Vegas Urology - Smoke Ranch
-
Las Vegas, Nevada, Estados Unidos, 89128
- Urology Specialists of Nevada - Northwest
-
Las Vegas, Nevada, Estados Unidos, 89169
- University Cancer Center
-
Las Vegas, Nevada, Estados Unidos, 89113
- Urology Specialists of Nevada - Southwest
-
Las Vegas, Nevada, Estados Unidos, 89128
- Oncology Las Vegas - Tenaya
-
Las Vegas, Nevada, Estados Unidos, 89183
- OptumCare Cancer Care at Fort Apache
-
Pahrump, Nevada, Estados Unidos, 89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Estados Unidos, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Estados Unidos, 89503
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Estados Unidos, 89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Concord, New Hampshire, Estados Unidos, 03301
- New Hampshire Oncology Hematology PA-Concord
-
Manchester, New Hampshire, Estados Unidos, 03103
- Solinsky Center for Cancer Care
-
Manchester, New Hampshire, Estados Unidos, 03103
- Elliot Hospital
-
-
New Jersey
-
Moorestown, New Jersey, Estados Unidos, 08057
- Virtua Samson Cancer Center
-
Mount Holly, New Jersey, Estados Unidos, 08060
- Virtua Memorial
-
Voorhees Township, New Jersey, Estados Unidos, 08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Glens Falls, New York, Estados Unidos, 12801
- Glens Falls Hospital
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
North Carolina
-
Kenansville, North Carolina, Estados Unidos, 28349
- ECU Health Oncology Kenansville
-
Kinston, North Carolina, Estados Unidos, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Estados Unidos, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Richlands, North Carolina, Estados Unidos, 28574
- ECU Health Oncology Richlands
-
Washington, North Carolina, Estados Unidos, 27889
- Marion L Shepard Cancer Center - ECU Health Beaufort Hospital
-
-
North Dakota
-
Fargo, North Dakota, Estados Unidos, 58103
- Essentia Health Cancer Center-South University Clinic
-
Jamestown, North Dakota, Estados Unidos, 58401
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Alliance, Ohio, Estados Unidos, 44601
- Aultman Alliance Community Hospital
-
Beavercreek, Ohio, Estados Unidos, 45431
- Indu and Raj Soin Medical Center
-
Boardman, Ohio, Estados Unidos, 44512
- Saint Elizabeth Boardman Hospital
-
Canton, Ohio, Estados Unidos, 44708
- Cleveland Clinic Mercy Hospital
-
Canton, Ohio, Estados Unidos, 44710
- Aultman Health Foundation
-
Centerville, Ohio, Estados Unidos, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Estados Unidos, 45459
- Dayton Physicians LLC-Miami Valley South
-
Cincinnati, Ohio, Estados Unidos, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Estados Unidos, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Estados Unidos, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cincinnati, Ohio, Estados Unidos, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Estados Unidos, 45255
- TriHealth Cancer Institute-Anderson
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Estados Unidos, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Dayton, Ohio, Estados Unidos, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Estados Unidos, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Estados Unidos, 45415
- Dayton Physician LLC - Englewood
-
Dayton, Ohio, Estados Unidos, 45409
- Premier Blood and Cancer Center
-
Findlay, Ohio, Estados Unidos, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Estados Unidos, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Estados Unidos, 45840
- Orion Cancer Care
-
Franklin, Ohio, Estados Unidos, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Estados Unidos, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Estados Unidos, 45331
- Wayne Hospital
-
Greenville, Ohio, Estados Unidos, 45331
- Dayton Physicians LLC-Wayne
-
Greenville, Ohio, Estados Unidos, 45331
- Miami Valley Cancer Care and Infusion
-
Kettering, Ohio, Estados Unidos, 45429
- Kettering Medical Center
-
Kettering, Ohio, Estados Unidos, 45409
- Greater Dayton Cancer Center
-
Kettering, Ohio, Estados Unidos, 45420
- First Dayton Cancer Care
-
Mansfield, Ohio, Estados Unidos, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Maumee, Ohio, Estados Unidos, 43537
- Toledo Clinic Cancer Centers-Maumee
-
Mayfield Heights, Ohio, Estados Unidos, 44124
- Hillcrest Hospital Cancer Center
-
Perrysburg, Ohio, Estados Unidos, 43551
- Mercy Health - Perrysburg Hospital
-
Sandusky, Ohio, Estados Unidos, 44870
- North Coast Cancer Care
-
Springfield, Ohio, Estados Unidos, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Estados Unidos, 45504
- Springfield Regional Medical Center
-
Strongsville, Ohio, Estados Unidos, 44136
- Cleveland Clinic Cancer Center Strongsville
-
Toledo, Ohio, Estados Unidos, 43623
- Mercy Health - Saint Anne Hospital
-
Toledo, Ohio, Estados Unidos, 43623
- Toledo Clinic Cancer Centers-Toledo
-
Troy, Ohio, Estados Unidos, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Estados Unidos, 45373
- Dayton Physicians LLC - Troy
-
Warren, Ohio, Estados Unidos, 44484
- Saint Joseph Warren Hospital
-
Warrensville Heights, Ohio, Estados Unidos, 44122
- South Pointe Hospital
-
Wooster, Ohio, Estados Unidos, 44691
- Cleveland Clinic Wooster Family Health and Surgery Center
-
Wright-Patterson Air Force Base, Ohio, Estados Unidos, 45433
- Wright-Patterson Medical Center
-
Youngstown, Ohio, Estados Unidos, 44501
- Saint Elizabeth Youngstown Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Baker City, Oregon, Estados Unidos, 97814
- Saint Alphonsus Cancer Care Center-Baker City
-
Bend, Oregon, Estados Unidos, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Estados Unidos, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Estados Unidos, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Estados Unidos, 97420
- Bay Area Hospital
-
Newberg, Oregon, Estados Unidos, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Estados Unidos, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Estados Unidos, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
Portland, Oregon, Estados Unidos, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Estados Unidos, 97225
- Providence Saint Vincent Medical Center
-
Redmond, Oregon, Estados Unidos, 97756
- Saint Charles Health System-Redmond
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, Estados Unidos, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem, Pennsylvania, Estados Unidos, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Bryn Mawr, Pennsylvania, Estados Unidos, 19010
- Bryn Mawr Hospital
-
Chambersburg, Pennsylvania, Estados Unidos, 17201
- Chambersburg Hospital
-
Chambersburg, Pennsylvania, Estados Unidos, 17201
- WellSpan Medical Oncology and Hematology
-
Collegeville, Pennsylvania, Estados Unidos, 19426
- Main Line Health Center-Collegeville
-
East Stroudsburg, Pennsylvania, Estados Unidos, 18301
- Pocono Medical Center
-
Easton, Pennsylvania, Estados Unidos, 18045
- Saint Luke's Hospital-Anderson Campus
-
Ephrata, Pennsylvania, Estados Unidos, 17522
- Ephrata Cancer Center
-
Exton, Pennsylvania, Estados Unidos, 19341
- Main Line Health Center-Exton
-
Gettysburg, Pennsylvania, Estados Unidos, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Estados Unidos, 17331
- WellSpan Medical Oncology and Hematology
-
Hazleton, Pennsylvania, Estados Unidos, 18201
- Lehigh Valley Hospital-Hazleton
-
Lebanon, Pennsylvania, Estados Unidos, 17042
- Sechler Family Cancer Center
-
Media, Pennsylvania, Estados Unidos, 19063
- Riddle Memorial Hospital
-
Newtown Square, Pennsylvania, Estados Unidos, 19073
- Bryn Mawr Health Center
-
Paoli, Pennsylvania, Estados Unidos, 19301
- Paoli Memorial Hospital
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Penn Presbyterian Medical Center
-
Pottstown, Pennsylvania, Estados Unidos, 19464
- Pottstown Hospital
-
Quakertown, Pennsylvania, Estados Unidos, 18951
- Saint Luke's Hospital-Quakertown Campus
-
Quakertown, Pennsylvania, Estados Unidos, 18951
- Saint Luke's Hospital - Upper Bucks Campus
-
Sayre, Pennsylvania, Estados Unidos, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
Wynnewood, Pennsylvania, Estados Unidos, 19096
- Lankenau Medical Center
-
York, Pennsylvania, Estados Unidos, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Estados Unidos, 17403
- WellSpan Health-York Hospital
-
York, Pennsylvania, Estados Unidos, 17403
- Cancer Care Associates of York
-
-
South Carolina
-
Greenwood, South Carolina, Estados Unidos, 29646
- Self Regional Healthcare
-
-
Texas
-
Bryan, Texas, Estados Unidos, 77802
- Saint Joseph Regional Cancer Center
-
-
Virginia
-
Mechanicsville, Virginia, Estados Unidos, 23116
- Bon Secours Memorial Regional Medical Center
-
Midlothian, Virginia, Estados Unidos, 23114
- Bon Secours Saint Francis Medical Center
-
Midlothian, Virginia, Estados Unidos, 23113
- Bon Secours Westchester Emergency Center
-
Norfolk, Virginia, Estados Unidos, 23505
- Bon Secours DePaul Medical Center
-
Portsmouth, Virginia, Estados Unidos, 23707
- Bon Secours Maryview Medical Center
-
Richmond, Virginia, Estados Unidos, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Estados Unidos, 23226
- Bon Secours Saint Mary's Hospital
-
Richmond, Virginia, Estados Unidos, 23230
- Bon Secours Cancer Institute at Reynolds Crossing
-
Richmond, Virginia, Estados Unidos, 23223
- Bon Secours Richmond Community Hospital
-
Richmond, Virginia, Estados Unidos, 23298
- VCU Massey Comprehensive Cancer Center
-
Suffolk, Virginia, Estados Unidos, 23435
- Bon Secours Health Center at Harbour View
-
-
Washington
-
Aberdeen, Washington, Estados Unidos, 98520
- Providence Regional Cancer System-Aberdeen
-
Bellevue, Washington, Estados Unidos, 98004
- Overlake Medical Center
-
Bellingham, Washington, Estados Unidos, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Estados Unidos, 98166
- Saint Anne Hospital
-
Centralia, Washington, Estados Unidos, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Estados Unidos, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Estados Unidos, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Estados Unidos, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Estados Unidos, 98003
- Saint Francis Hospital
-
Issaquah, Washington, Estados Unidos, 98029
- Swedish Cancer Institute-Issaquah
-
Kennewick, Washington, Estados Unidos, 99336
- Kadlec Clinic Hematology and Oncology
-
Lacey, Washington, Estados Unidos, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Estados Unidos, 98499
- Saint Clare Hospital
-
Longview, Washington, Estados Unidos, 98632
- PeaceHealth Saint John Medical Center
-
Port Townsend, Washington, Estados Unidos, 98368
- Jefferson Healthcare
-
Poulsbo, Washington, Estados Unidos, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Renton, Washington, Estados Unidos, 98055
- Valley Medical Center
-
Seattle, Washington, Estados Unidos, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Estados Unidos, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Estados Unidos, 98122-5711
- Swedish Medical Center-Cherry Hill
-
Sedro-Woolley, Washington, Estados Unidos, 98284
- PeaceHealth United General Medical Center
-
Shelton, Washington, Estados Unidos, 98584
- Providence Regional Cancer System-Shelton
-
Silverdale, Washington, Estados Unidos, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Tacoma, Washington, Estados Unidos, 98405
- Northwest Medical Specialties PLLC
-
Tacoma, Washington, Estados Unidos, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Estados Unidos, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Estados Unidos, 99362
- Providence Saint Mary Regional Cancer Center
-
Yakima, Washington, Estados Unidos, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Yelm, Washington, Estados Unidos, 98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Huntington, West Virginia, Estados Unidos, 25701
- Edwards Comprehensive Cancer Center
-
-
Wisconsin
-
Appleton, Wisconsin, Estados Unidos, 54911
- ThedaCare Regional Cancer Center
-
Ashland, Wisconsin, Estados Unidos, 54806
- Duluth Clinic Ashland
-
Ashland, Wisconsin, Estados Unidos, 54806
- Northwest Wisconsin Cancer Center
-
Berlin, Wisconsin, Estados Unidos, 54923
- ThedaCare Cancer Care - Berlin
-
Burlington, Wisconsin, Estados Unidos, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chippewa Falls, Wisconsin, Estados Unidos, 54729
- Marshfield Clinic-Chippewa Center
-
Cudahy, Wisconsin, Estados Unidos, 53110
- Aurora Saint Luke's South Shore
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Marshfield Medical Center-EC Cancer Center
-
Germantown, Wisconsin, Estados Unidos, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Estados Unidos, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Estados Unidos, 54311
- Aurora BayCare Medical Center
-
Hayward, Wisconsin, Estados Unidos, 54843
- Essentia Health-Hayward Clinic
-
Kenosha, Wisconsin, Estados Unidos, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Estados Unidos, 54601
- Gundersen Lutheran Medical Center
-
Ladysmith, Wisconsin, Estados Unidos, 54848
- Marshfield Medical Center - Ladysmith
-
Marinette, Wisconsin, Estados Unidos, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Estados Unidos, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Estados Unidos, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Estados Unidos, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Estados Unidos, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Estados Unidos, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Racine, Wisconsin, Estados Unidos, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Spooner, Wisconsin, Estados Unidos, 54801
- Essentia Health-Spooner Clinic
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Summit, Wisconsin, Estados Unidos, 53066
- Aurora Medical Center in Summit
-
Superior, Wisconsin, Estados Unidos, 54880
- Essentia Health Saint Mary's Hospital - Superior
-
Two Rivers, Wisconsin, Estados Unidos, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha, Wisconsin, Estados Unidos, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Estados Unidos, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Estados Unidos, 54401
- Marshfield Clinic-Wausau Center
-
Wauwatosa, Wisconsin, Estados Unidos, 53226
- Aurora Cancer Care-Milwaukee West
-
Weston, Wisconsin, Estados Unidos, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Estados Unidos, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Wyoming
-
Cheyenne, Wyoming, Estados Unidos, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Estados Unidos, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Estados Unidos, 82801
- Welch Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
RANDOMIZATION (STEP 1): Patient must be >= 18 years of age
-
RANDOMIZATION (STEP 1): Patient must have pathologically confirmed non-squamous non-small cell lung carcinoma (NSCLC). Patients with NSCLC not otherwise specified (NOS) are eligible. Mixed tumors will be categorized by predominant cell type. If small cell elements are present, the patient is ineligible
-
RANDOMIZATION (STEP 1): Patient must have metastatic stage IVA or IVB disease (includes M1a, M1b, and M1c), according to the 8th edition of the lung cancer TNM classification system. Recurrent metastatic NSCLC ineligible for curative therapy (in the treating investigator's opinion) is also allowed
-
RANDOMIZATION (STEP 1): Patient's tumor must be known negative for EGFR tyrosine kinase inhibitor (TKI) sensitizing mutations (for example at a minimum, negative for EGFR Exon 19 deletions, EGFR exon 20 insertions, and Exon 21 L858R, L861Q mutations ) AND negative for ALK gene rearrangements (by fluorescence in situ hybridization [FISH], next generation sequencing [NGS], or immunohistochemistry [IHC]) by routine Clinical Laboratory Improvement Amendments (CLIA)- or Food and Drug Administration (FDA)-certified clinical testing methods. CLIA or FDA approved circulating tumor deoxyribonucleic acid (DNA) testing is acceptable as an alternative to tissue testing
-
RANDOMIZATION (STEP 1): Patient must have radiographic and/or clinical progression (per local investigator assessment) following one, but only one, line of platinum-based chemotherapy AND one, but only one, line of prior checkpoint inhibitor (anti-PD-1 or PD-L1) immunotherapy, either concurrently or sequentially in either order. A minimum of two doses of prior immunotherapy is required. Only one prior line of therapy is allowed if patients received chemotherapy and immunotherapy together (patients may not receive subsequent single agent chemotherapy), and greater than two prior lines of therapy are not allowed.
- NOTE: Lines of therapy are defined by clinical or radiographic progression. For patients with recurrent metastatic NSCLC following treatment for stage 1-3 NSCLC, platinum-based chemotherapy received within 12 months of recurrence and/or immunotherapy received within 6 months of recurrence will meet the requirement for prior chemotherapy and/or immunotherapy but subsequent receipt of more immunotherapy and/or platinum-based chemotherapy is also allowed.
- NOTE: Prior anti-VEGF antibody therapy (ie bevacizumab) is allowed. Prior ipilimumab, or investigational agents not excluded below, in combination with the required prior therapies above are allowed.
- NOTE: Prior receipt of one or two lines of targeted therapy for ROS1, RET, MET, BRAF, ERBB2/HER2, or KRAS G12C positive NSCLC is allowed and will not count toward the line of therapy limit. However, progression is still required after chemotherapy and immunotherapy as above. Patients with ROS1, RET, MET positive NSCLC are strongly encouraged to get appropriate targeted therapy (such as crizotinib, entrectinib, lorlatinib, selpercatinib, pralsetinib, capmatinib, tepotinib, or another investigational, off-label, or approved agent directed against ROS1, RET, or MET positive NSCLC) prior to participation and will be stratified.
- NOTE: No prior predominantly VEGFR directed TKI therapy (such as cabozantinib, lenvatinib, or sitravantinib) is allowed, except for the agents named above.
-
RANDOMIZATION (STEP 1): The investigator must document the intended chemotherapy regimen should their patient be randomized to Arm C (docetaxel and ramucirumab, OR single agent chemotherapy - docetaxel, gemcitabine, paclitaxel, nab-paclitaxel). The patient must not have received the selected chemotherapy agent previously for metastatic disease
-
RANDOMIZATION (STEP 1): Any prior chemotherapy (based on administration schedule) must have been completed in greater than or equal to the following times prior to randomization:
- FDA approved targeted oral therapy must be completed >= 1 week prior
- Chemotherapy and/or immunotherapy must be completed >= 2 weeks prior
- Prior investigational agents must be completed >= 4 weeks prior.
-
RANDOMIZATION (STEP 1): Prior radiation therapy is allowed with a 2 week washout prior to randomization. Patient must not receive any systemic treatment with radionuclides within 6 weeks prior to randomization. Patient must have no clinically relevant ongoing complication from prior radiation therapy
-
RANDOMIZATION (STEP 1): Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen (in the opinion of the treating physician) are eligible for this trial
-
RANDOMIZATION (STEP 1): Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents (such as anthracycline or HER2-directed antibody therapy, but not prior checkpoint inhibitor therapy), must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients must be class 2B or better
-
RANDOMIZATION (STEP 1): Patient must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have met the eligibility criteria outlined above
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have measurable disease as defined by RECIST v1.1. Measurements must be obtained within 4 weeks prior to randomization/registration
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have recovered to equal to or less than grade 1 toxicities related to prior treatment, unless toxicities are clinically non significant and/or stable on supportive therapy (as determined by the treating physician)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Absolute neutrophil count >= 1,500/mcL (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Platelets >= 100,000/mcL (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Hemoglobin >= 9 g/dL (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (for patients with Gilbert's disease total bilirubin must be =< 3 x ULN) (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Creatinine =< 1.5 x ULN OR calculated (Cockcroft-Gault formula) or measured creatinine clearance >= 50 mL/min/1.73m^2 (normalized to body surface area [BSA]) for patients with creatinine levels greater than 1.5 times the institutional normal creatinine =< 1.5 X ULN or creatinine clearance >= 50ml/min/1.73m^2 (obtained within 2 weeks prior to randomization)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not be pregnant or breast-feeding due to the unknown effects of cabozantinib and nivolumab on human development and for the potential risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization/registration to rule out pregnancy.
- A patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after completion of treatment on the study
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have clinically significant gastrointestinal bleeding within 6 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have pulmonary hemorrhage or hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have active drug induced pneumonitis within 3 months prior to randomization. Prior immune mediated pneumonitis of grade 3 or 4 are not eligible regardless of time window
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have current radiographic evidence of tumor invading major blood vessel, evidence of tumor cavitation > 1 cm, evidence of tumor invading the gastrointestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or evidence of endotracheal or mainstem endobronchial tumor
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have peptic ulcer disease, known malabsorption syndrome, bowel obstruction or gastric outlet obstruction within 3 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have abdominal fistula, GI perforation, or intra-abdominal abscess within 6 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have grade 3 or greater infection, or infection requiring intravenous systemic treatment within 14 days prior to randomization. Patients must be off antibiotics at the time of randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have serious non-healing wound/ulcer/bone fracture within 28 days prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have history of organ transplant
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have concurrent symptomatic untreated hypothyroidism
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have history of major surgery within 3 months prior to randomization, minor surgery within 28 days prior to randomization, other minor procedures within 7 days prior to randomization, or clinically relevant ongoing complications from prior procedures
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have concurrent uncontrolled hypertension defined as sustained blood pressure (BP) > 160 mm Hg systolic, or > 100 mm Hg diastolic despite optimal antihypertensive treatment
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have unstable angina pectoris, clinically-significant cardiac arrhythmias, stroke (including transient ischemic attack [TIA]), or myocardial infarction within 6 months prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients must not have a diagnosis of deep vein thrombosis/pulmonary embolism (DVT/PE) within 6 months of randomization unless stable, asymptomatic, and treated with low-molecular-weight heparin (LMWH) or a permitted oral anticoagulant for at least 7 days before randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not be receiving anticoagulants (i.e., warfarin, aspirin, clopidogrel) except:
- Prophylactic use of low-dose aspirin (100 mg po daily or less) and/or low dose molecular weight heparin (LMWH) is permitted.
- Therapeutic doses of low dose molecular weight heparin (LMWH) or specified direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban are allowed in patients without untreated brain metastases who are on a stable dose 7 days prior to study randomization, and without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not receive strong CYP3A4 inducers (e.g., dexamethasone (> 1 mg daily dosing), phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, and St. John's Wort) within 7 days prior to randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must have corrected QT interval calculated by the Fridericia formula (QTcF) =< 500 msec within 28 days prior to Step 1 randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must be able to swallow tablets
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not be on continuous systemic treatment with corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days prior to randomization, with the following exceptions:
- Inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- Patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption).
- Physiologic replacement doses of systemic corticosteroids are permitted, if < 10 mg/day prednisone equivalents. A brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with brain metastases are eligible as follows:
- Previously treated brain metastases must have been treated with radiation > 2 weeks prior to randomization or surgery > 3 months prior to randomization OR
- Untreated (active) brain metastases are allowed if they are clinically asymptomatic, < 1 cm, non-hemorrhagic, the patient is not on systemic anticoagulation, and the investigator believes that central nervous system (CNS) specific treatment is unlikely to be required during the first 3 months of study treatment.
- NOTE: Symptomatic leptomeningeal disease is NOT allowed
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not have known active autoimmune disease or known history of autoimmune disease for which recurrence may affect vital organ function or require immune suppressive treatment including systemic corticosteroids (e.g., immune-related neurologic disease, multiple sclerosis, autoimmune neuropathy, Guillain-Barre syndrome, etc.).
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with known history of human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with known history of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral at time of randomization (suppressive therapy is allowed, if indicated)
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load at time of randomization
-
RANDOMIZATION (STEP 1 - ALL TREATMENT ARMS): Patient must not have had any prior allergic reaction or hypersensitivity to study drug components or related drugs (multitargeted small molecule tyrosine kinase inhibitors or checkpoint inhibitor monoclonal antibodies)
-
STEP 2 (CROSSOVER ARM Z): Patient must have met all eligibility requirements for Step 1 at time of registration to Step 1 to be eligible for Step 2
-
STEP 2 (CROSSOVER ARM Z): Patient must have radiographic progressive disease per RECIST criteria after >= 2 cycles of therapy on Arm C. The scan showing progression must be completed within 6 weeks prior to Step 2 registration
-
STEP 2 (CROSSOVER ARM Z): Patient must not have intervening anticancer treatment or major surgical procedure(s) between Step 1 and Step 2, except palliative radiation which was completed >= 1 week prior to registration to Step 2
-
STEP 2 (CROSSOVER ARM Z): Patient may not have central nervous system progression, but patients with stable CNS disease are allowed
-
STEP 2 (CROSSOVER ARM Z): Patient must have an ECOG performance status 0-2
-
STEP 2 (CROSSOVER ARM Z): Patient must have recovered to equal to or less than grade 1 toxicities related to prior treatment, unless the adverse event(s) are clinically non significant and/or stable on supportive therapy (as determined by the treating physician)
-
STEP 2 (CROSSOVER ARM Z): Absolute neutrophil count >= 1,500/mcL (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Platelets >= 100,000/mcL (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Hemoglobin >= 9 g/dL (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Total bilirubin =< 1.5 x institutional ULN (for patients with Gilbert's disease total bilirubin must be =< 3 x ULN) (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): AST(SGOT) and ALT(SGPT) =< 2.5 x ULN (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Creatinine =< 1.5 x ULN OR calculated (Cockcroft-Gault formula) or measured creatinine clearance >= 50 mL/min/1.73m^2 (normalized to BSA) for patients with creatinine levels greater than 1.5 times the institutional normal creatinine =< 1.5 X ULN or creatinine clearance >= 50ml/min/1.73m^2 (obtained within 2 weeks prior to registration to Step 2)
-
STEP 2 (CROSSOVER ARM Z): Patient must have corrected QT interval calculated by the Fridericia formula (QTcF) =< 500 ms within 28 days prior to Step 2 registration
-
STEP 2 (CROSSOVER ARM Z): Patient must not have any intercurrent illness or disease complication that the investigator believes would limit the ability to safely tolerate the combination of cabozantinib and nivolumab
-
STEP 2 (CROSSOVER ARM Z): Patient must not be pregnant or breast-feeding due to the unknown effects of cabozantinib and nivolumab on human development and for the potential risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to registration to Step 2 to rule out pregnancy.
- A patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).
-
STEP 2 (CROSSOVER ARM Z): Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after completion of treatment on the study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Step 1, Arm A (cabozantinib S-malate)
Patients in Step 1, Arm A receive cabozantinib S-malate PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Undergo CT
Outros nomes:
Given PO
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo blood collection
Outros nomes:
|
|
Experimental: Step 1, Arm B (cabozantinib S-malate, nivolumab)
Patients in Step 1, Arm B receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Undergo CT
Outros nomes:
Given PO
Outros nomes:
Undergo ECHO
Outros nomes:
Given IV
Outros nomes:
Undergo blood collection
Outros nomes:
|
|
Comparador Ativo: Step 1, Arm C (standard chemotherapy)
Patients in Step 1, Arm C receive ramucirumab IV over 30-60 minutes and docetaxel IV over 1 hour on day 1, or docetaxel IV over 1 hour on days 1 and 8, or gemcitabine hydrochloride IV on days 1 and 8, or paclitaxel IV over 3 hours on day 1, or nab-paclitaxel IV over 30 minutes on days 1 and 8. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity and at the discretion of the treating physician. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo CT
Outros nomes:
Undergo ECHO
Outros nomes:
Undergo blood collection
Outros nomes:
Given IV
Outros nomes:
Given PO
Outros nomes:
Given IV
Outros nomes:
|
|
Experimental: Step 2, Arm Z (cabozantinib S-malate, nivolumab)
Patients in Step 2, Arm Z receive cabozantinib S-malate PO QD and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients may continue to receive therapy after investigator-assessed RECIST 1.1 defined progression, including stable clinical and performance status and have potential for continued clinical benefit. Patients also undergo ECHO as clinically indicated, CT throughout the trial, and collection of blood on study. |
Undergo CT
Outros nomes:
Given PO
Outros nomes:
Undergo ECHO
Outros nomes:
Given IV
Outros nomes:
Undergo blood collection
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival (PFS) for patient population with non-squamous no-small cell lung cancer (NSCLC)
Prazo: After 58 events (From time of randomization to documented disease progression [site review of imaging] or death from any cause, whichever occurs first)
|
The final analysis of PFS will be performed when the full information of PFS is reached (i.e., 58 events for each of the two primary comparisons). The two primary comparisons of PFS will each use a logrank test stratified on the randomization stratification factors with a one-sided type I error rate of 10%. Estimates of PFS including medians and confidence intervals, will be calculated using the Kaplan-Meier method. Cox proportional hazards models, stratified, on the same factors, will be used to estimate the treatment hazard ratios. At the final analyses, in the event that both primary PFS comparisons of the combination of nivolumab with cabozantinib and cabozantinib alone versus the standard chemotherapy are statistically significant, PFS will be compared between the two experimental arms (combination of nivolumab with cabozantinib versus [vs.] cabozantinib alone), using a stratified log rank test with a one-sided type I error rate of 10%. |
After 58 events (From time of randomization to documented disease progression [site review of imaging] or death from any cause, whichever occurs first)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall survival (OS) for each arm
Prazo: From time of randomization to documented disease progression (site review of imaging) or death from any cause, whichever occurs first, assessed up to 3 years
|
The final analysis of OS will be performed when the full information of PFS is reached (i.e., 58 events for each of the two primary comparisons). OS will be tested in a hierarchical fashion if the primary comparison of PFS between treatment arms is statistically significant, using a log rank test stratified on the randomization stratification factors with a one-sided type I error rate of 10%. Estimates of OS, including medians and confidence intervals, will be calculated using the Kaplan-Meier method. Cox proportional hazards models, stratified, on the same factors, will be used to estimate the treatment hazard ratios. OS will be further tested in a hierarchical fashion if the comparison of PFS between the two experimental arms is statistically significant. Point estimates of all endpoints will be accompanied by the corresponding two-sided 80% confidence intervals. Subset analyses of PFS and OS by treatment arm will be estimated and compared within subsets. |
From time of randomization to documented disease progression (site review of imaging) or death from any cause, whichever occurs first, assessed up to 3 years
|
|
Best objective response for each arm
Prazo: Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
Will be evaluated via Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Response rates (complete response [CR] + partial response [PR]) and toxicity will be compared using Fisher's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. Modeling procedures will implement backward selection; variables significant at the 0.10 level in the univariate setting will be chosen for inclusion in an initial full model, and at each step the least significant variable will be removed from the model. Only those covariates with p < 0.05 will remain in any final models, unless there are factors identified by the study team as crucial to model interpretation. Point estimates of all endpoints will be accompanied by the corresponding two-sided 80% confidence intervals. |
Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
|
Toxicity profile of monotherapy with cabozantinib, and the combination of nivolumab and cabozantinib
Prazo: Up to 3 years after completion of study treatment
|
Will be determined using the Common Terminology Criteria for Adverse Events (CTCAE) criteria. Response rates (complete response [CR] + pathologic response [PR]) and toxicity will be compared using Fisher's exact tests with a one-sided type I error rate of 10%; multivariable logistic regression modeling will be used to adjust for the effect of any covariates that are associated with these categorical outcomes. Modeling procedures will implement backward selection; variables significant at the 0.10 level in the univariate setting will be chosen for inclusion in an initial full model, and at each step the least significant variable will be removed from the model. Only those covariates with p < 0.05 will remain in any final models, unless there are factors identified by the study team as crucial to model interpretation. Point estimates of all endpoints will be accompanied by the corresponding two-sided 80% confidence intervals. |
Up to 3 years after completion of study treatment
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The RECIST1.1 response at each time point
Prazo: Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
The measurement of each time point will be performed using the revised CHOI criteria will be only applied to arms A and B, which will include anti-angiogenic therapy. Both the RECIST1.1 and revised CHOI criteria will assess the overall best response as CR, partial PR, stable disease (SD), or progressive disease (PD). Their concordance will be assessed using the weighted Cohen's kappa coefficient (k) with quadratic weights. As a rule of thumb, the level of concordance between the two criteria will be considered poor (k <0), slight (k 0-0.20), fair (k 0.21-0.40), moderate (k 0.41-0.60), substantial (k 0.61-0.80), and almost perfect (k 0.81 - 1). |
Every 6 weeks for the first year on study, and then every 12 weeks after year one
|
|
Agreement between central view and site review in terms of progression-free survival
Prazo: After the completion of study treatment
|
The progression status and the progression time will be assessed in agreement. The progression status is a binary measurement and the agreement will be assessed using the Cohen's kappa coefficient. For progression time, will assess the temporal agreement using the method developed by Zeng et al. |
After the completion of study treatment
|
|
Correlative biomarker research
Prazo: After the completion of study treatment
|
Correlative biomarker research will be performed on tissue and blood specimens collected within this trial. |
After the completion of study treatment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Joel W Neal, ECOG-ACRIN Cancer Research Group
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Neoplasias por local
- Neoplasias
- Doenças Respiratórias
- Doenças pulmonares
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Neoplasias Pulmonares
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Técnicas de investigação
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Hidrocarbonetos
- Cicloparaffinas
- Hidrocarbonetos, aliciclicos
- Hidrocarbonetos, cíclicos
- Terpenos
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Taxóides
- Ciclodecanos
- Diterpenos
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Economia de saúde e organizações
- Álbumins
- Economia
- Docetaxel
- Nivolumabe
- Paclitaxel ligado à albumina
- Gemcitabina
- Ramucirumabe
- Paclitaxel
- Manipulação de amostras
- Paclitaxel com 130 nm de albumina
- Cabozantinib
- Impostos
Outros números de identificação do estudo
- NCI-2020-01541
- U10CA180820 (Concessão/Contrato do NIH dos EUA)
- NCI-2020-01541 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- EA5191 (Outro identificador: CTEP)
- EA5191 (Outro identificador: ECOG-ACRIN Cancer Research Group)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .